Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)

•Available scales do not assess the social dimension of multiple sclerosis.•We developed a new Patient-Reported Outcome Measure to evaluate patient autonomy.•Autonomy and associated taxonomy were first defined using a sociologic approach.•The Multiple Sclerosis Autonomy Scale includes 10 social dime...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders 2024-12, Vol.92, p.105925, Article 105925
Hauptverfasser: Donzé, Cécile, Mekies, Claude, Paillot, Géraud, Vermersch, Patrick, Montagu, Guillaume, Brechenmacher, Lucie, Civet, Alexandre, Pau, David, Mouzawak, Catherine, Cohen, Mikael
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 105925
container_title Multiple sclerosis and related disorders
container_volume 92
creator Donzé, Cécile
Mekies, Claude
Paillot, Géraud
Vermersch, Patrick
Montagu, Guillaume
Brechenmacher, Lucie
Civet, Alexandre
Pau, David
Mouzawak, Catherine
Cohen, Mikael
description •Available scales do not assess the social dimension of multiple sclerosis.•We developed a new Patient-Reported Outcome Measure to evaluate patient autonomy.•Autonomy and associated taxonomy were first defined using a sociologic approach.•The Multiple Sclerosis Autonomy Scale includes 10 social dimensions and 36 items. In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients’ autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment. This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts’ opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire. The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 soc
doi_str_mv 10.1016/j.msard.2024.105925
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04817989v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2211034824005017</els_id><sourcerecordid>3118304066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c273t-86e9140d51347f8002f70640c52ada75211d8d06339911db07b56ce82e69c26a3</originalsourceid><addsrcrecordid>eNp9kc9uEzEQxi0EolXpEyAhH9vDBv9b7y4Sh6gFipSKQ-BsOfas4mgdL7Y3Vd-Ax8ZhmxzxxaNvfjOjmQ-h95QsKKHy427hk452wQgTRak7Vr9Cl4xRWhFey9fnWLQX6DqlHSlP1lRI-hZd8E4w3rDmEv25hwMMYfSwzzj0WOM9POFRZ1eEKsIYYgaLw5RN8IA96DRFwH2IJyjhJ5e32E9DduMAOJkBYkgufcJ5C_jxpK9POl5OOeyDfy6SLombx_VyffsOven1kOD65b9Cv75--Xn3UK1-fPt-t1xVhjU8V62Ejgpia8pF07eEsL4hUhBTM211U5elbWuJ5LzrSrghzaaWBloGsjNMan6Fbue-Wz2oMTqv47MK2qmH5UodNSJa2nRtd6CFvZnZMYbfE6SsvEsGhkHvIUxJcUpbTgSRsqB8Rk3ZMUXoz70pUUfH1E79c0wdHVOzY6Xqw8uAaePBnmtO_hTg8wxAOcnBQVTJlKMbsC6CycoG998BfwGR96eE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118304066</pqid></control><display><type>article</type><title>Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Donzé, Cécile ; Mekies, Claude ; Paillot, Géraud ; Vermersch, Patrick ; Montagu, Guillaume ; Brechenmacher, Lucie ; Civet, Alexandre ; Pau, David ; Mouzawak, Catherine ; Cohen, Mikael</creator><creatorcontrib>Donzé, Cécile ; Mekies, Claude ; Paillot, Géraud ; Vermersch, Patrick ; Montagu, Guillaume ; Brechenmacher, Lucie ; Civet, Alexandre ; Pau, David ; Mouzawak, Catherine ; Cohen, Mikael</creatorcontrib><description>•Available scales do not assess the social dimension of multiple sclerosis.•We developed a new Patient-Reported Outcome Measure to evaluate patient autonomy.•Autonomy and associated taxonomy were first defined using a sociologic approach.•The Multiple Sclerosis Autonomy Scale includes 10 social dimensions and 36 items. In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients’ autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment. This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts’ opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire. The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 social dimensions (five dimensions with 19 questions concerning all the patients, and five dimensions with 17 questions concerning specific patients). The internal consistency of the final questionnaire was good for all the dimensions, as the Cronbach's alpha coefficient ranged from 0.77 to 0.85 depending on dimensions. The construct validity of the questionnaire was also confirmed. Our research allowed to build the first PROM designed to evaluate the autonomy of patients suffering from MS: the Multiple Sclerosis Autonomy Scale (MSAS). A confirmatory study, conducted in patients with MS using this validated questionnaire, is currently conducted.</description><identifier>ISSN: 2211-0348</identifier><identifier>ISSN: 2211-0356</identifier><identifier>EISSN: 2211-0356</identifier><identifier>DOI: 10.1016/j.msard.2024.105925</identifier><identifier>PMID: 39423727</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Autonomy ; Female ; Humans ; Life Sciences ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - psychology ; Multiple Sclerosis Autonomy Scale (MSAS) ; Patient Reported Outcome Measures ; Patient reported outcomes measure ; Personal Autonomy ; Psychometric methods ; Psychometrics - standards ; Reproducibility of Results ; Severity of Illness Index ; Surveys and Questionnaires - standards</subject><ispartof>Multiple sclerosis and related disorders, 2024-12, Vol.92, p.105925, Article 105925</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><rights>Attribution - NonCommercial - NoDerivatives</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c273t-86e9140d51347f8002f70640c52ada75211d8d06339911db07b56ce82e69c26a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39423727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04817989$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Donzé, Cécile</creatorcontrib><creatorcontrib>Mekies, Claude</creatorcontrib><creatorcontrib>Paillot, Géraud</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Montagu, Guillaume</creatorcontrib><creatorcontrib>Brechenmacher, Lucie</creatorcontrib><creatorcontrib>Civet, Alexandre</creatorcontrib><creatorcontrib>Pau, David</creatorcontrib><creatorcontrib>Mouzawak, Catherine</creatorcontrib><creatorcontrib>Cohen, Mikael</creatorcontrib><title>Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)</title><title>Multiple sclerosis and related disorders</title><addtitle>Mult Scler Relat Disord</addtitle><description>•Available scales do not assess the social dimension of multiple sclerosis.•We developed a new Patient-Reported Outcome Measure to evaluate patient autonomy.•Autonomy and associated taxonomy were first defined using a sociologic approach.•The Multiple Sclerosis Autonomy Scale includes 10 social dimensions and 36 items. In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients’ autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment. This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts’ opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire. The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 social dimensions (five dimensions with 19 questions concerning all the patients, and five dimensions with 17 questions concerning specific patients). The internal consistency of the final questionnaire was good for all the dimensions, as the Cronbach's alpha coefficient ranged from 0.77 to 0.85 depending on dimensions. The construct validity of the questionnaire was also confirmed. Our research allowed to build the first PROM designed to evaluate the autonomy of patients suffering from MS: the Multiple Sclerosis Autonomy Scale (MSAS). A confirmatory study, conducted in patients with MS using this validated questionnaire, is currently conducted.</description><subject>Adult</subject><subject>Autonomy</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - psychology</subject><subject>Multiple Sclerosis Autonomy Scale (MSAS)</subject><subject>Patient Reported Outcome Measures</subject><subject>Patient reported outcomes measure</subject><subject>Personal Autonomy</subject><subject>Psychometric methods</subject><subject>Psychometrics - standards</subject><subject>Reproducibility of Results</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires - standards</subject><issn>2211-0348</issn><issn>2211-0356</issn><issn>2211-0356</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9uEzEQxi0EolXpEyAhH9vDBv9b7y4Sh6gFipSKQ-BsOfas4mgdL7Y3Vd-Ax8ZhmxzxxaNvfjOjmQ-h95QsKKHy427hk452wQgTRak7Vr9Cl4xRWhFey9fnWLQX6DqlHSlP1lRI-hZd8E4w3rDmEv25hwMMYfSwzzj0WOM9POFRZ1eEKsIYYgaLw5RN8IA96DRFwH2IJyjhJ5e32E9DduMAOJkBYkgufcJ5C_jxpK9POl5OOeyDfy6SLombx_VyffsOven1kOD65b9Cv75--Xn3UK1-fPt-t1xVhjU8V62Ejgpia8pF07eEsL4hUhBTM211U5elbWuJ5LzrSrghzaaWBloGsjNMan6Fbue-Wz2oMTqv47MK2qmH5UodNSJa2nRtd6CFvZnZMYbfE6SsvEsGhkHvIUxJcUpbTgSRsqB8Rk3ZMUXoz70pUUfH1E79c0wdHVOzY6Xqw8uAaePBnmtO_hTg8wxAOcnBQVTJlKMbsC6CycoG998BfwGR96eE</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Donzé, Cécile</creator><creator>Mekies, Claude</creator><creator>Paillot, Géraud</creator><creator>Vermersch, Patrick</creator><creator>Montagu, Guillaume</creator><creator>Brechenmacher, Lucie</creator><creator>Civet, Alexandre</creator><creator>Pau, David</creator><creator>Mouzawak, Catherine</creator><creator>Cohen, Mikael</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20241201</creationdate><title>Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)</title><author>Donzé, Cécile ; Mekies, Claude ; Paillot, Géraud ; Vermersch, Patrick ; Montagu, Guillaume ; Brechenmacher, Lucie ; Civet, Alexandre ; Pau, David ; Mouzawak, Catherine ; Cohen, Mikael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c273t-86e9140d51347f8002f70640c52ada75211d8d06339911db07b56ce82e69c26a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Autonomy</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - psychology</topic><topic>Multiple Sclerosis Autonomy Scale (MSAS)</topic><topic>Patient Reported Outcome Measures</topic><topic>Patient reported outcomes measure</topic><topic>Personal Autonomy</topic><topic>Psychometric methods</topic><topic>Psychometrics - standards</topic><topic>Reproducibility of Results</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires - standards</topic><toplevel>online_resources</toplevel><creatorcontrib>Donzé, Cécile</creatorcontrib><creatorcontrib>Mekies, Claude</creatorcontrib><creatorcontrib>Paillot, Géraud</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>Montagu, Guillaume</creatorcontrib><creatorcontrib>Brechenmacher, Lucie</creatorcontrib><creatorcontrib>Civet, Alexandre</creatorcontrib><creatorcontrib>Pau, David</creatorcontrib><creatorcontrib>Mouzawak, Catherine</creatorcontrib><creatorcontrib>Cohen, Mikael</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Multiple sclerosis and related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donzé, Cécile</au><au>Mekies, Claude</au><au>Paillot, Géraud</au><au>Vermersch, Patrick</au><au>Montagu, Guillaume</au><au>Brechenmacher, Lucie</au><au>Civet, Alexandre</au><au>Pau, David</au><au>Mouzawak, Catherine</au><au>Cohen, Mikael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)</atitle><jtitle>Multiple sclerosis and related disorders</jtitle><addtitle>Mult Scler Relat Disord</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>92</volume><spage>105925</spage><pages>105925-</pages><artnum>105925</artnum><issn>2211-0348</issn><issn>2211-0356</issn><eissn>2211-0356</eissn><abstract>•Available scales do not assess the social dimension of multiple sclerosis.•We developed a new Patient-Reported Outcome Measure to evaluate patient autonomy.•Autonomy and associated taxonomy were first defined using a sociologic approach.•The Multiple Sclerosis Autonomy Scale includes 10 social dimensions and 36 items. In multiple sclerosis (MS), the measure of the loss of autonomy appears to be particularly relevant to provide adapted and personalized responses to improve the quality of care in routine clinical practice. In this context, this research aimed to develop a new patient-reported outcome measure (PROM) evaluating MS patients’ autonomy, in order to provide an easy-to-use tool in the context of the relations between healthcare professionals and patients with MS, and to be used in future clinical trials for treatment assessment. This research was conducted in two consecutive stages. First, a preliminary questionnaire was generated using an innovative sociological approach for MS (after literature review, patient interviews, experts’ opinion, and patient focus groups). This questionnaire was then completed by patients with MS, before the reduction of the scale while maintaining relevant information, using a principal component analysis. The internal consistency reliability was assessed using the Cronbach's alpha coefficient. The external validity was evaluated using an analysis of variance to estimate the relation between the reduced questionnaire dimension scores and disease severity classes assessed by the SymptoMScreen questionnaire. The first qualitative step of the research led to provide a definition of disease-related autonomy as perceived by patients (to be able to carry out the roles the patient thinks the most important whether or not he/she receives assistance) as well as an associated taxonomy. On this basis, a preliminary questionnaire of 131 items grouped into 13 social dimensions was generated (seven dimensions with 63 questions concerning all the patients, and six dimensions with 68 questions concerning specific patients). This questionnaire was completed on a web platform by 653 analyzable patients with MS. Their main characteristics were as follows: female patients: 83.6 %, mean age at MS diagnosis: 34.8 ± 10.5 years, age ≥40 years at data collection: 68.1 %, MS duration ≥5 years: 68.4 %, severe MS (SymptoMScreen score ≥30): 36.8 %. On the basis on completed 131-item questionnaires, it was reduced in a 36-item short form of 10 social dimensions (five dimensions with 19 questions concerning all the patients, and five dimensions with 17 questions concerning specific patients). The internal consistency of the final questionnaire was good for all the dimensions, as the Cronbach's alpha coefficient ranged from 0.77 to 0.85 depending on dimensions. The construct validity of the questionnaire was also confirmed. Our research allowed to build the first PROM designed to evaluate the autonomy of patients suffering from MS: the Multiple Sclerosis Autonomy Scale (MSAS). A confirmatory study, conducted in patients with MS using this validated questionnaire, is currently conducted.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39423727</pmid><doi>10.1016/j.msard.2024.105925</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2211-0348
ispartof Multiple sclerosis and related disorders, 2024-12, Vol.92, p.105925, Article 105925
issn 2211-0348
2211-0356
2211-0356
language eng
recordid cdi_hal_primary_oai_HAL_hal_04817989v1
source MEDLINE; Alma/SFX Local Collection
subjects Adult
Autonomy
Female
Humans
Life Sciences
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - diagnosis
Multiple Sclerosis - psychology
Multiple Sclerosis Autonomy Scale (MSAS)
Patient Reported Outcome Measures
Patient reported outcomes measure
Personal Autonomy
Psychometric methods
Psychometrics - standards
Reproducibility of Results
Severity of Illness Index
Surveys and Questionnaires - standards
title Development of a new patient-reported outcome measure for patients with multiple sclerosis: the Multiple Sclerosis Autonomy Scale (MSAS)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A26%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20new%20patient-reported%20outcome%20measure%20for%20patients%20with%20multiple%20sclerosis:%20the%20Multiple%20Sclerosis%20Autonomy%20Scale%20(MSAS)&rft.jtitle=Multiple%20sclerosis%20and%20related%20disorders&rft.au=Donz%C3%A9,%20C%C3%A9cile&rft.date=2024-12-01&rft.volume=92&rft.spage=105925&rft.pages=105925-&rft.artnum=105925&rft.issn=2211-0348&rft.eissn=2211-0356&rft_id=info:doi/10.1016/j.msard.2024.105925&rft_dat=%3Cproquest_hal_p%3E3118304066%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3118304066&rft_id=info:pmid/39423727&rft_els_id=S2211034824005017&rfr_iscdi=true